What is Juniper Biomedical?
Juniper Biomedical is developing a precision neuromodulation platform designed to offer patients less invasive, safer, and more effective therapeutic options. This innovative technology aims to address unmet needs in patient care through advanced capabilities in neurological treatment. The company's focus on precision therapy positions it as a key player in the evolving medical device and biotech landscape.
How much funding has Juniper Biomedical raised?
Juniper Biomedical has raised a total of $3M across 2 funding rounds:
Grant
$1M
Angel/Seed
$2M
Grant (2024): $1M with participation from NIH SPARC Neuromod Prize
Angel/Seed (2024): $2M led by ATMA Capital and Hub Angel Investment Group Fund V
Key Investors in Juniper Biomedical
NIH SPARC Neuromod Prize
The NIH SPARC Neuromod Prize is a grant awarded by the National Institutes of Health, likely supporting research and development in neuromodulation technologies.
ATMA Capital
ATMA Capital is a venture capital firm focused on making control investments in new businesses, crafting strategic plans, and executing operational initiatives to foster long-term success and growth.
Hub Angel Investment Group Fund V
Hub Angel Investment Group is an angel investment syndicate that specializes in funding early-stage technology and life science companies, providing not only capital but also strategic guidance and industry connections.
What's next for Juniper Biomedical?
The recent major strategic investment signals a pivotal growth phase for Juniper Biomedical. This influx of capital is expected to accelerate the development and commercialization of its neuromodulation platform, potentially expanding its market reach and enhancing its therapeutic offerings. The company is poised to leverage this backing to further its mission of improving patient outcomes through cutting-edge medical technology, marking a significant step in its enterprise-level development trajectory.
